Melanoma
FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy
The marketing authorization makes Thermo Fisher’s SeCore CDx HLA Sequencing System the first and so far only commercially available HLA typing companion diagnostic.
Castle Biosciences Q3 Revenues up 58 Percent on Strong Melanoma Test Volume
The company reported volume growth across its skin cancer and skin disease diagnostics as it builds a customer base for newer menu additions.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.
PamGene Gains CE-IVD Registration for Immunotherapy Guidance Tests
The company's blood-based IOpener-NSCLC and IOpener-melanoma assays help guide therapy in non-small cell lung cancer and advanced melanoma patients, respectively.